<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Oncogenic mutations in the KRAS2, NRAS, or FLT3 gene are detected in more than 50% of patients with de novo <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain><z:mp ids='MP_0011356'>RAS</z:mp> mutations are also prevalent in de novo <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), especially <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> and juvenile myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>However, few studies have examined these genetic lesions in therapy-related <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain><z:mp ids='MP_0004026'>Monosomy</z:mp> 7/del(7q) and <z:mp ids='MP_0004026'>monosomy</z:mp> 5/del(5q) represent the most common cytogenetic abnormalities in <z:e sem="disease" ids="C1292780" disease_type="Neoplastic Process" abbrv="">therapy-related MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and are strongly associated with prior exposure to <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Mutational analysis of bone marrow specimens from a well-characterized cohort of 26 t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients with abnormalities of chromosomes 5 and/or 7 revealed 3 with <z:mp ids='MP_0011356'>RAS</z:mp> mutations </plain></SENT>
<SENT sid="5" pm="."><plain>Further analyses of 23 of these cases uncovered one FLT3 internal tandem duplication and five TP53 mutations </plain></SENT>
<SENT sid="6" pm="."><plain>The four patients with <z:mp ids='MP_0011356'>RAS</z:mp> or FLT3 mutations had <z:mp ids='MP_0004026'>monosomy</z:mp> 7, including one with abnormalities of chromosomes 5 and 7 </plain></SENT>
<SENT sid="7" pm="."><plain>One specimen demonstrated mutations in both KRAS2 and TP53 </plain></SENT>
<SENT sid="8" pm="."><plain><z:mp ids='MP_0011356'>RAS</z:mp> and FLT3 mutations, which are thought to stimulate the proliferation of <z:hpo ids='HP_0001909'>leukemia</z:hpo> cells, appear to be less common in t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> than in de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, whereas TP53 mutations are more frequent </plain></SENT>
</text></document>